Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038311
Status:
COMPLETED
Last Update Posted:
2015-05-04
First Post:
2002-05-30
Brief Title:
Safety and Efficacy of PN-152243PN-196444 in the Prevention of Thrombocytopenia
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Safety and Efficacy of PN-152243PN-196444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy Adriamycin and Ifosfamide AI
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Intensive chemotherapy is associated with significant thrombocytopenia often requiring platelet transfusion to maintain platelet counts This investigational drug has demonstrated the ability to increase platelet counts This study will test the safety and efficacy of an investigational drug in the prevention of thrombocytopenia in patients with high-risk sarcoma receiving AI AdriamycinIfosfamide chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None